Entering text into the input field will update the search result below

KemPharm out-licenses U.S. rights to Apadaz for up to $56M; shares up 35% premarket

Oct. 31, 2018 6:50 AM ETZevra Therapeutics, Inc. (ZVRA) StockBy: Douglas W. House, SA News Editor1 Comment
  • Thinly traded nano cap KemPharm (NASDAQ:KMPH) is up 35% premarket on light volume in response to its collaboration and license agreement with KVK Tech for U.S. commercial rights to APADAZ (benzhydrocodone and acetaminophen tablets).
  • Under the terms of the deal, KMPH will receive up to $3.4M in pre-launch payments, up to $53M in sales milestones and half of net profits based on achieving certain sales levels.
  • KVK will be responsible for all regulatory and commercialization expenses.

Recommended For You

About ZVRA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ZVRA--
Zevra Therapeutics, Inc.